HBeAg- positive (studie 026): behandling med entecavir i op til 96 uger (n = 141) gav kumulative responsrater på 30% for HBV DNA < 300 kopier/ ml ved PCR og 85% for ALAT- normalisering og 17% for HBeAg- serokonvertering.
HBeAg positive (study 026): treatment with entecavir for up to 96 weeks (n = 141) resulted in cumulative response rates of 30% for HBV DNA < 300 copies/ ml by PCR, 85% for ALT normalisation and 17% for HBeAg seroconversion.